Biota completes new flu trial
Thursday, 31 July, 2008
Biota Holdings [ASX: BTA] has completed the Phase II trials of its influenza treatment CS-8958, with Phase III trials set to commence later this year.
CS-8958 is a long-acting neuraminidase inhibitor [LANI], and is co-owned by Daiichi-Sankyo.
Several hundred flu patients participated in the double-blind trial, which was conducted to the standards of the Japanese Pharmaceuticals and Medical Devices Agency.
The trial revealed that one dose of CS-8958 produced results indistinguishable from 75mg of oseltamivir administered twice daily for five days.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
